The FDA has recently approved pegloticase injection co-administered with methotrexate in uncontrolled gout following the findings from the MIRROR randomized clinical trial presented at EULAR 2022. touchIMMUNOLOGY were delighted to speak with Dr. John K. Botson (Orthopedic Physicians Alaska, Anchorage, AK, USA) to discuss the rationale for combining methotrexate with pegloticase in the treatment of uncontrolled gout and the aims, design and findings from the clinical trial assessing the safety and efficacy of this co-therapy.
The abstract ‘A Randomized, Double Blind, Placebo Controlled, Multicenter, Study of Methotrexate combined with Pegloticase in Patients with Uncontrolled Gout.‘ (Abstract number: OP0171) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
Questions
- What are the challenges in the management of patients with gout who do not respond to oral urate-lowering therapy? (0:24)
- What is the rationale for the use of methotrexate combined with pegloticase in these patients? (1:20)
- What were the aims, design and eligibility criteria of the clinical trial you are presenting? (2:18)
- What was the primary endpoint and how well was it achieved? (3:28)
- What were the safety and tolerability findings of the study? (4:28)
- What does the approval of this combination mean for patients with uncontrolled gout? (5:20)
Disclosures: John Botson discloses consulting for Horizon Therapeutics; receiving grant/ research support from Horizon Therapeutics and Radius Health; serving on advisory boards for Abbvie, Aurinia, Eli Lilly, Horizon Therapeutics and Novartis; receiving honoraria from Abbvie, Aurinia, Amgen, Chemocentryx, Eli Lilly, Horizon Therapeutics and Novartis; and participating in speaker’s bureaus for Abbvie, Amgen, Chemocentryx, Eli Lilly, Horizon Therapeutics and Novartis.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
